39 Results

People

  1. Hyman
    Hyman
  2. Iasonos
    Iasonos
  3. Drilon
    Drilon
  4. Aghajanian
    Aghajanian
  5. Grisham
    Grisham
  6. Schram
    Schram
  7. Berger
    Berger
  8. Solit
    Solit
  9. Spriggs
    Spriggs
  10. Diamond
    Diamond

Groups

  1. Department of Medicine (39)
  2. Early Drug Development Service (39)
  3. Solid Tumor Oncology Division (39)
  4. Epidemiology and Biostatistics (21)
  5. Gynecologic Medicine Service (20)
  6. GSK Faculty (19)
  7. Human Oncology and Pathogenesis Program (19)
  8. Biostatistics Service (17)
  9. Tow Center for Developmental Oncology (TCDO) (15)
  10. Gynecology Disease Management Team (13)
  1. "aged"
  2. "Early Drug Development Service"
Formats
  1. Journal Article (39)
Groups
  1. Department of Medicine (39)
  2. Early Drug Development Service (39)
  3. Solid Tumor Oncology Division (39)
  4. Epidemiology and Biostatistics (21)
  5. Gynecologic Medicine Service (20)
  6. GSK Faculty (19)

More Groups

People
  1. David Hyman (36)
  2. Alexia Iasonos (12)
  3. Alexander Drilon (10)
  4. Marc Ladanyi (10)
  5. Ahmet Zehir (8)
  6. Alison Schram (8)

More People

Years
  1. 2022 (1)
  2. 2021 (2)
  3. 2020 (7)
  4. 2019 (7)
  5. 2018 (7)
  6. 2017 (3)

More Years

Publications
  1. Gynecologic Oncology (5)
  2. JCO Precision Oncology (4)
  3. Cancer (3)
  4. Cancer Discovery (3)
  5. Investigational New Drugs (3)
  6. New England Journal of Medicine (3)

More Publications

Publishers
  1. Elsevier Inc. (7)
  2. American Society of Clinical Oncology (5)
  3. American Association for Cancer Research (4)
  4. Springer (4)
  5. Massachusetts Medical Society (3)
  6. Nature Publishing Group (3)

More Publishers

Results (39)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors
    Journal Article

    Borazanci, E.; Schram, A. M.; Garralda, E.; Brana, I.; Vieito Villar, M.; Spreafico, A.; Oliva, M.; Lakhani, N. J.; Hoffman, K.; Hallett, R. M.; more...
    ESMO Open (2022)

    Fulltext@MSK | Save
  • Clinical and morphologic characteristics of extracellular signal-regulated kinase inhibitor-associated retinopathy
    Journal Article

    Francis, J. H.; Canestraro, J.; Haggag-Lindgren, D.; Harding, J. J.; Diamond, E. L.; Drilon, A.; Li, B. T.; Iyer, G.; Schram, A. M.; Abramson, D. H.
    Ophthalmology Retina (2021)

    Fulltext@MSK | Save
  • Characterization and management of ERK inhibitor associated dermatologic adverse events: Analysis from a nonrandomized trial of ulixertinib for advanced cancers
    Journal Article

    Wu, J.; Liu, D.; Offin, M.; Lezcano, C.; Torrisi, J. M.; Brownstein, S.; Hyman, D. M.; Gounder, M. M.; Abida, W.; Drilon, A.; more...
    Investigational New Drugs (2021)

    Fulltext@MSK | Save
  • Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer
    Journal Article

    Drilon, A.; Oxnard, G. R.; Tan, D. S. W.; Loong, H. H. F.; Johnson, M.; Gainor, J.; McCoach, C. E.; Gautschi, O.; Besse, B.; Cho, B. C.; more...
    New England Journal of Medicine (2020)

    Fulltext@MSK | Save
  • Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients
    Journal Article

    Ross, D. S.; Liu, B.; Schram, A. M.; Razavi, P.; Lagana, S. M.; Zhang, Y.; Scaltriti, M.; Bromberg, J. F.; Ladanyi, M.; Hyman, D. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials
    Journal Article

    Hong, D. S.; DuBois, S. G.; Kummar, S.; Farago, A. F.; Albert, C. M.; Rohrberg, K. S.; van Tilburg, C. M.; Nagasubramanian, R.; Berlin, J. D.; Federman, N.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations
    Journal Article

    Rosen, E. Y.; Goldman, D. A.; Hechtman, J. F.; Benayed, R.; Schram, A. M.; Cocco, E.; Shifman, S.; Gong, Y.; Kundra, R.; Solomon, J. P.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
    Journal Article

    Rubinstein, M. M.; Hyman, D. M.; Caird, I.; Won, H.; Soldan, K.; Seier, K.; Iasonos, A.; Tew, W. P.; O’Cearbhaill, R. E.; Grisham, R. N.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • Development of genome-derived tumor type prediction to inform clinical cancer care
    Journal Article

    Penson, A.; Camacho, N.; Zheng, Y.; Varghese, A. M.; Al-Ahmadie, H.; Razavi, P.; Chandarlapaty, S.; Vallejo, C. E.; Vakiani, E.; Gilewski, T.; more...
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer
    Journal Article

    Stasenko, M.; Tunnage, I.; Ashley, C. W.; Rubinstein, M. M.; Latham, A. J.; Da Cruz Paula, A.; Mueller, J. J.; Leitao, M. M. Jr; Friedman, C. F.; Makker, V.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save